Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EPIK-B2 maintenance therapy with alpelisib + trastuzumab + pertuzumab in HER2-positive advanced breast cancer with PIK3CA mutation
2019-002741-37Phase 3Active
- Sponsor
- Novartis
- Start
- Feb 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in breast cancer comparing Alpelisib + trastuzumab + pertuzumab with Placebo + trastuzumab + pertuzumab (2 arms). Primary endpoint: Part 1 safety run-in. Started Feb 2020; status: active.
02
Drugs
alpelisib
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2019-002741-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-002741-37.